At the IGTP TODAY
A total of 19 women researchers affiliated with the Germans Trias i Pujol Research Institute (IGTP) feature in the April 2026 edition of the Ranking of Spanish Women Researchers and Women Researchers in Spain, reflectig the relevance of the research conducted both at the institute and across the Can Ruti Campus.
The symposium has become a key event for sharing knowledge and experiences around these conditions.
The Institute has taken part in BIOSPAIN 2025, the leading biotechnology event in southern Europe, with the aim of strengthening its knowledge and technology transfer strategy, showcasing its innovation capabilities, and fostering new collaborations with companies, investors, and stakeholders across the biomedical ecosystem.
On Friday 28 February, HUGTiP and IGTP held a new edition of their event to mark Rare Disease Day. The event brought together healthcare professionals and researchers to share knowledge and experiences in the field. The program also included the patient perspective in the final part of the event.
The Instituto de Investigación Sanitaria IGTP has secured a total of €6,518,867 for various research projects and researcher contracts within the Acción Estratégica en Salud 2024 calls.
IGTP has received grants for six research projects in two calls from the Spanish Research Agency, under the State Plan for Scientific and Technical Research and Innovation 2021-2023.
The Spanish Ministry of Science, Innovation and Universities (MICIU) has awarded €1.7 million, and the European Commission an additional €466,000, to support the development of a gene therapy for Friedreich's ataxia by Biointaxis, a spin-off from IGTP.
Researchers from IGTP and BSC-CNS have discovered new genetic mechanisms related to spinocerebellar ataxia type 37. Their research, published in the journal Human Genetics, employed advanced techniques such as CRISPR/Cas9 gene editing, real-time large DNA sequencing and machine learning. The study deepens our understanding of this inherited disease, leading to more precise diagnoses and improved genetic counselling for patients.
The Centre for the Development of Industrial Technology (CDTI) and the Carlos III Health Institute (ISCII) will fund the project with 1.8 million euros within the R&D&I call linked to Personalised Medicine and Advanced Therapies in the framework of the Strategic Project for the Recovery and Economic Transformation for Vanguard Health (PERTE for Vanguard Health) in gene therapy for Friedreich's ataxia.
The article describing the new SCA49 subtype has been published in the journal Brain Communications, and is featured as a highlight by its Editorial Board. The new ataxia subtype has been identified by studying members of one family from the island of Menorca. The finding provides a better understanding of the pathological basis of ataxia and opens the door to pre-symptomatic diagnoses and genetic counselling for people with the disorder.
